Cardinal Health announced its cancer screening offerings from FUJIFILM Healthcare Americas Corporation and Polymedco that can be done either outside of a doctor's office or with less invasive procedures can help combat the increase in cancer-related deaths due to late-stage diagnoses from pandemic-related delays.
According to a report in JAMA Oncology, nearly 10 million cancer screenings for breast, colon and prostate cancer were missed in the U.S. since the pandemic began. Researchers recently reported a more than 40% decline in colon cancer diagnoses alone during the pandemic, a statistic that points to missed screenings, not fewer cases.
During the pandemic, some health systems and health plans began proactively mailing screening collection kits to patients, rather than waiting for patients to come in for a routine visit or colonoscopy. Cardinal Health works with Polymedco to offer OC-Auto FIT, which detects small amounts of blood in stool – an early indication of colon cancer. Different than a colonoscopy, patients don't have to prep in advance of the test and can do the stool specimen collection at home.
As liver cancer is one of the top-three leading causes of cancer-related deaths worldwide, in November 2020, Cardinal Health became the first distributor of Fujifilm's innovative solution, the µTASWako i30 Immunoanalyzer System testing for liver biomarkers AFP-L3 and DCP using a simple blood draw for biomarkers of hepatocellular carcinoma (HCC), the most common type of liver cancer.
Visit Cardinal Health for more
